구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | therapeutic tumor infiltrating lymphocytes (therapeutic tumor infiltrating lymphocytes) Iovance Biotherapeutics, Inc.·Melanoma (Skin) 33 trials |
|---|---|
Overview Program | therapeutic tumor infiltrating lymphocytes |
Overview Company | Iovance Biotherapeutics, Inc. |
Overview Modality | CGT |
Overview Target | Melanoma (Skin) |
Overview Indication | Breast Cancer; Metastatic Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Advances in adoptive cell therapy for ovarian cancer.. Ovarian cancer remains the most lethal gynecological malignancy worldwide, with late-stage diagnosis, high recurrence rates, and chemoresistance posing persistent clinical challenges. Adoptive cell therapy (ACT), a rapidly advancing immunotherapeutic strategy, offers promising efficacy with low systemic toxicity and has emerged as a compelling… |
Toxicology CRS | Reported |
Clinical Safety signal | Advances in adoptive cell therapy for ovarian cancer.. Ovarian cancer remains the most lethal gynecological malignancy worldwide, with late-stage diagnosis, high recurrence rates, and chemoresistance posing persistent clinical challenges. Adoptive cell therapy (ACT), a rapidly advancing immunotherapeutic strategy, offers promising efficacy with low systemic toxicity and has emerged as a compelling… |
Clinical Selected reported efficacy | ORR 38.5% |
Clinical Reported ORR | 38.5% |
Clinical Result source | ClinicalTrials.gov NCT01701674 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01701674 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | therapeutic tumor infiltrating lymphocytes (therapeutic tumor infiltrating lymphocytes) Iovance Biotherapeutics, Inc.·Melanoma (Skin) 33 trials |
|---|---|
Overview Program | therapeutic tumor infiltrating lymphocytes |
Overview Company | Iovance Biotherapeutics, Inc. |
Overview Modality | CGT |
Overview Target | Melanoma (Skin) |
Overview Indication | Breast Cancer; Metastatic Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Advances in adoptive cell therapy for ovarian cancer.. Ovarian cancer remains the most lethal gynecological malignancy worldwide, with late-stage diagnosis, high recurrence rates, and chemoresistance posing persistent clinical challenges. Adoptive cell therapy (ACT), a rapidly advancing immunotherapeutic strategy, offers promising efficacy with low systemic toxicity and has emerged as a compelling… |
Toxicology CRS | Reported |
Clinical Safety signal | Advances in adoptive cell therapy for ovarian cancer.. Ovarian cancer remains the most lethal gynecological malignancy worldwide, with late-stage diagnosis, high recurrence rates, and chemoresistance posing persistent clinical challenges. Adoptive cell therapy (ACT), a rapidly advancing immunotherapeutic strategy, offers promising efficacy with low systemic toxicity and has emerged as a compelling… |
Clinical Selected reported efficacy | ORR 38.5% |
Clinical Reported ORR | 38.5% |
Clinical Result source | ClinicalTrials.gov NCT01701674 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01701674 |
추천 비교
추천 비교